Qilu Pharmaceutical’s Generic Version of Vyndaqel Receives NMPA Marketing Approval
The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic version...
Jiangsu Yuyue Medical Teams Up with China Unicom for Digital Healthcare Innovation
Shanghai-based Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223) has announced a strategic partnership with China...
Ascentage Pharma’s THDBH120 Receives NMPA Approval for Phase Ib Clinical Trial
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...
Shineco Inc. Acquires 80% Stake in ‘Internet+Medical Care’ Platform Meitong Tech for USD 20 Million
Shineco Inc. (NASDAQ: SISI), a U.S.-based company, has signed an investment agreement with Beijing Dongfang...
Zhangzhou Pien Tze Huang’s PZH2113 Receives NMPA Clinical Trial Approval for Lymphoma Treatment
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436), a renowned traditional Chinese medicine (TCM)...
Tonghua Dongbao Pharmaceuticals’ THDBH120 Receives NMPA Approval for Phase II Clinical Trial
Tonghua Dongbao Pharmaceuticals (SHA: 600867), based in China, has announced that the National Medical Products...
DK Medical Technology Secures ‘Hundreds of Millions’ in Series E Financing for Expansion
DK Medical Technology Co. Ltd., a Suzhou-based developer of vascular intervention balloon products, has reportedly...
Shanghai Fudan-Zhangjiang and Hanhui Pharmaceutical End Marketing Deal for Libaoduo
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505), a Chinese biopharmaceutical company, has reached...
Luye Pharma’s Once-Weekly Parkinson’s Disease Treatment Receives NMPA Approval
Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from the...
Fudan-Zhangjiang Bio-Pharmaceutical Advances Aminolevulinic Acid Study for Glioma Visualization
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the first subject...
Novartis Moves Toward Full Ownership of MorphoSys with Shareholder Squeeze-Out
Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, is proceeding to fully acquire MorphoSys AG...
China Expands Controlled Substances Catalogue to Include Three Additional Substances
The Ministry of Public Security, National Health Commission, and National Medical Products Administration in China...
Dizal Pharmaceutical’s Golidocitinib Wins NMPA Approval for Relapsed/Refractory PTCL
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China established in 2017, has...
Shanghai Fosun Pharmaceutical Sells Stake in Gland Pharma for USD 211 Million
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the sale of...
Jiuzhou Pharmaceutical Shuts Down Two Subsidiaries to Streamline Operations
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a pharmaceutical company based in China, has announced...
Keymed Biosciences’ CM313 Shows Promise in Treating Immune Thrombocytopenia, NEJM Study Says
Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has published results from...
Xencor Reclaims Rights to Plamotamab After Janssen Halts Development
Xencor Inc. (NASDAQ: XNCR), a U.S.-based biotechnology company, has announced that Johnson & Johnson (J&J,...
AbbVie’s Skyrizi Secures FDA Approval for Ulcerative Colitis, Expands Treatment Portfolio
AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has approved...
Genrix Biopharmaceutical and Chongqing Pharmaceutical Group Form Strategic Partnership to Boost Market Launch
Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a biopharmaceutical company based in China, has entered...
AstraZeneca’s Gracell Biotechnologies to Expand Cell Therapy Manufacturing in China
Gracell Biotechnologies, a China-based cell therapy specialist owned by AstraZeneca (AZ; NASDAQ: AZN), is reportedly...